N. Kauff

A. Zauber, T. Church, S. Winawer, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor Board

A. Berchuck, G. Frampton, A. Armstrong, 2022, The oncologist.

Effect of Mammography on Breast Cancer Risk in Women with Mutations in BRCA1 or BRCA2

K. Offit, M. Robson, S. Chuai, 2006, Cancer Epidemiology Biomarkers & Prevention.

Clinicopathologic significance of DNA mismatch repair protein defects and endometrial cancer in women 40years of age and younger.

D. Levine, R. Barakat, N. Kauff, 2011, Gynecologic oncology.

How should women with early-onset endometrial cancer be evaluated for lynch syndrome?

N. Kauff, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oophorectomy in carriers of BRCA mutations [3]

T. Rebbeck, B. Weber, K. Offit, 2002 .

Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers

Susan M. Domchek, Timothy R. Rebbeck, T. Rebbeck, 2009, Journal of the National Cancer Institute.

Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2

Mads Thomassen, Stephen Fox, Dieter Niederacher, 2011, Breast Cancer Research.

The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.

N. Schultz, Jianjiong Gao, D. Levine, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.

T. Rebbeck, R. Eeles, C. Hudis, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development and Validation of a Clinical Score for Predicting Risk of Adenoma at Screening Colonoscopy

A. Zauber, T. Church, S. Winawer, 2015, Cancer Epidemiology, Biomarkers & Prevention.

BRCA Mutations in Women with Ductal Carcinoma In situ

C. Hudis, K. Offit, J. Boyd, 2007, Clinical Cancer Research.

Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer.

J. Satagopan, K. Offit, T. Kirchhoff, 2004, Journal of the National Cancer Institute.

High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes.

H. Hricak, M. Gönen, E. Sala, 2017, Radiology.

Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

J. Satagopan, K. Offit, J. Boyd, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families

K. Offit, M. Robson, Z. Stadler, 2014, Breast Cancer Research and Treatment.

Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199).

M. Gail, M. Greene, M. Sherman, 2019, JNCI cancer spectrum.

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.

Mads Thomassen, Nina Ditsch, Muhammad Usman Rashid, 2015, JAMA.

Genome-wide association studies of cancer predisposition.

Peter R. Thom, K. Offit, T. Kirchhoff, 2010, Hematology/oncology clinics of North America.

The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study

Stephanie A Cohen, F. Couch, O. Olopade, 2016, British Journal of Cancer.

Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families

K. Offit, M. Robson, Z. Stadler, 2010, Breast Cancer Research and Treatment.

Genome-wide association studies of cancer.

Kenneth Offit, Peter R. Thom, Bert Gold, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations

C. Hudis, K. Offit, E. Brogi, 2003, Cancer.

Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers.

A. Iasonos, D. Hyman, D. Spriggs, 2011, Gynecologic oncology.

Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium.

H. Beltran, E. Schaeffer, E. Antonarakis, 2018, JCO precision oncology.

TRAUMA IN THE OBSTETRIC PATIENT : EVALUATION AND MANAGEMENT

N. Kauff, N. Tejani, 1998 .

SGO White Paper on ovarian cancer: etiology, screening and surveillance.

Robert L Coleman, J. Schorge, R. Coleman, 2010, Gynecologic oncology.

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.

Sandra L. Halverson, A. Whittemore, L. Kiemeney, 2016, Gynecologic oncology.

BRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews

K. Offit, T. Kirchhoff, M. Robson, 2004, Clinical Cancer Research.

Screening for familial ovarian cancer: a ray of hope and a light to steer by.

K. Long, N. Kauff, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.

Nandita Mitra, Kenneth Offit, Tessa Cigler, 2005, Journal of the National Cancer Institute.

Ovarian carcinoma screening in women at intermediate risk

K. Offit, R. Barakat, M. Robson, 2005, Cancer.

Four-year follow-up of outcomes following risk-reducing salpingo-oophorectomy in BRCA mutation carriers

C. Hudis, K. Offit, J. Boyd, 2005 .

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

J. Satagopan, C. Hudis, L. Norton, 2002, The New England journal of medicine.

Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.

B. Karlan, A. Berchuck, J. Lancaster, 2007, Gynecologic oncology.

Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families

G. Parmigiani, K. Offit, M. Robson, 2002, Journal of medical genetics.

The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome

P. Møller, H. Kitchener, U. Menon, 2019, Genetics in Medicine.

Management of BRCA Mutation-Negative Patients

N. Kauff, D. Gallagher, 2008 .

Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity.

K. Offit, R. Barakat, P. Sabbatini, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Surgical risk-reduction in carriers of BRCA mutations: where do we go from here?

R. Barakat, N. Kauff, 2004, Gynecologic oncology.

Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.

J. Satagopan, L. Norton, K. Offit, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RE: Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction.

Jinbo Chen, T. Rebbeck, S. Domchek, 2015, Journal of the National Cancer Institute.

Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant.

D. Altshuler, W. Foulkes, C. Hudis, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hereditary ovarian cancer in Ashkenazi Jews

K. Offit, M. Robson, N. Kauff, 2004, Familial Cancer.

Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk

W. Chung, P. Hall, V. Pankratz, 2013, PLoS Genetics.

Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers

W. Chung, R. Nussbaum, D. Steinemann, 2015, PloS one.

DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

Olufunmilayo I. Olopade, Mads Thomassen, Torben A. Kruse, 2014, PLoS genetics.

Early detection and prognosis of ovarian cancer using serum YKL-40.

H. Thaler, E. Holland, P. Sabbatini, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract P3-08-07: Distinct biological signatures describe differences in BRCA mutated subgroups

Afshin Mashadi-Hossein, T. Hyslop, P. Marcom, 2019, Poster Session Abstracts.

The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing

L. Kiemeney, M. Pike, M. Beckmann, 2011, Clinical Cancer Research.

Utility of Immunohistochemistry in Predicting Microsatellite Instability in Endometrial Carcinoma

J. Shia, N. Kauff, R. Soslow, 2007, The American journal of surgical pathology.

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation

Mark E. Robson, Kenneth Offit, Jaya M. Satagopan, 2002 .

Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers.

J. Satagopan, K. Offit, S. Jhanwar, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Treatment of menorrhagia in women undergoing hematopoietic stem cell transplantation

E. Stier, A. Amsterdam, N. Kauff, 2004, Bone Marrow Transplantation.

Large Prospective Study of Ovarian Cancer Screening in High-Risk Women: CA125 Cut-Point Defined by Menopausal Status

A. Berchuck, M. Greene, S. Buys, 2011, Cancer Prevention Research.

Disease genes and chromosomes: disease maps of the human genome.Chromosome 12.

N. Kauff, F. Gilbert, 2000, Genetic Testing.

ATR mutations in endometrial cancer: a window into the role of mismatch repair defects.

N. Kauff, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

50 – Cancer of the Ovary

D. Chi, Z. Fuks, N. Kauff, 2010 .

Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.

M. Pike, T. Rebbeck, R. Eeles, 2016, JAMA oncology.

BRCA Mutations in Womenwith Ductal Carcinoma In situ

C. Hudis, K. Offit, J. Boyd, 2007 .

Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life.

M. Robson, J. Ostroff, L. Hann, 2003, Gynecologic oncology.

Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma.

D. Levine, D. Hyman, D. Spriggs, 2012, Gynecologic oncology.

A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer.

R. Barakat, N. Kauff, J. Carter, 2009, Gynecologic oncology.

Screening and prevention of hereditary gynecologic cancers.

N. Kauff, S. Kehoe, 2007, Seminars in oncology.

SpinThin, a simple, inexpensive technique for preparation of thin‐layer cervical cytology from liquid‐based specimens

M. Melamed, N. Kauff, W. Khalbuss, 2000, Cancer.

Disease genes and chromosomes: disease maps of the human genome. Chromosome 9.

N. Kauff, F. Gilbert, 2001, Genetic Testing.

Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.

B. Karlan, A. Berchuck, J. Lancaster, 2015, Gynecologic oncology.

Socioeconomic and Demographic Barriers Associated with Delays in Pancreatic Cancer Germline Genetic Testing

C. Alfano, N. Kauff, Xianghui Zou, 2023, medRxiv.

Assessment of the prevalence of de novo mutations in the BRCA1 and BRCA2 genes

K. Offit, M. Robson, Z. Stadler, 2011, Clinical genetics.

Weighing options for cancer risk reduction in carriers of BRCA1 and BRCA2 mutations.

Z. Stadler, N. Kauff, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Modeling genetic risk of breast cancer.

Kenneth Offit, K. Offit, N. Kauff, 2007, JAMA.

Discriminatory accuracy and potential clinical utility of genomic profiling for breast cancer risk in BRCA-negative women

C. Hudis, K. Offit, M. Gönen, 2011, Breast Cancer Research and Treatment.

Breast cancer: Oophorectomy for BRCA1 ER-negative disease—an open debate

M. Robson, N. Kauff, 2015, Nature Reviews Clinical Oncology.

Is There a Role for Ovarian Cancer Screening in High-Risk Women?

A. Berchuck, L. Havrilesky, N. Kauff, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.

Sandra L. Halverson, A. Whittemore, L. Kiemeney, 2016, Gynecologic oncology.

Identification of six new susceptibility loci for invasive epithelial ovarian cancer

Yurii B. Shvetsov, Simon G. Coetzee, Dennis J. Hazelett, 2014, Nature Genetics.

Screening for familial ovarian cancer: a ray of hope and a light to steer by.

K. Long, N. Kauff, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A review of the challenges faced in the conservative treatment of young women with endometrial carcinoma and risk of ovarian cancer.

R. Barakat, N. Kauff, J. Carter, 2009, Gynecologic oncology.

Reservations About Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations-Reply.

M. Pike, N. Kauff, C. Shu, 2017, JAMA oncology.

Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study.

R. Wenham, M. Greene, R. Moser, 2019, Gynecologic oncology.

Risk of metachronous breast cancer after BRCA mutation–associated ovarian cancer

C. Hudis, K. Offit, K. Nathanson, 2013, Cancer.

American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers.

W. Rubinstein, K. Hughes, E. Stoffel, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.

A. Whittemore, F. Couch, B. Bonanni, 2015 .

Reducing the risk of gynecologic cancer in the Lynch syndrome.

K. Offit, N. Kauff, 2006, The New England journal of medicine.

Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant.

D. Altshuler, W. Foulkes, C. Hudis, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of BRCA-Negative Hereditary Breast Cancer Families

N. Kauff, 2007 .

Multi-center prospective analysis of risk-reducing salpingo-oophorectomy to prevent BRCA-associated breast and ovarian cancer.

T. Rebbeck, L. Norton, K. Offit, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

A. Whittemore, D. Steinemann, F. Couch, 2014, PLoS genetics.